CVRx

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVRx reports stellar Q4 results, eyes growth opportunities in 2023

CVRx's strong performance in 2022, highlighted by revenue growth and operational advancements, sets a positive trajectory for the company. While challenges persist in European market expansion, the focus on key growth areas and strategic initiatives positions CVRx for continued success in 2023.

CVRx reports stellar Q1 performance, eyes label expansions for growth

CVRx's Q1 2023 showcased robust revenue growth, operational progress, and increased guidance for the full year. While challenges like rising expenses and inventory management exist, the company's focus on profitability, label expansions, and market expansion programs position it well for future success.

CVRx excels in Q2 with robust revenue growth and market expansion

CVRx's strong Q2 performance, revenue growth, and strategic initiatives position the company for future success in the heart failure market.
While facing challenges in clinical trial enrollment and regulatory uncertainties, CVRx's focus on market expansion and pricing optimization presents opportunities for sustained growth.
With a clear roadmap for revenue improvement, cash flow optimization, and market penetration, CVRx is poised to capitalize on the growing demand for its therapies.

CVRx reports robust Q3 performance, raises full-year revenue guidance

CVRx delivered a strong performance in Q3 2023, marked by revenue growth and operational advancements.
While facing challenges like net losses and regulatory uncertainties, the company is well-positioned for future growth.
Opportunities lie in market expansion, revenue growth, and maintaining operational efficiencies for sustained success.

CVRx posts robust Q4 earnings, eyes growth amid leadership transition

CVRx reported strong financial performance in Q4 2023, with significant revenue growth and operational achievements.
The company faces challenges in managing expenses, designing new clinical studies, and balancing growth strategies.
Opportunities lie in expanding market opportunities, engaging stakeholders for new programs, and pursuing aggressive growth strategies.
Guidance for 2024 indicates a positive outlook with revenue projections and strategic focus on growth and operational efficiency.

CVRx reports revenue growth in Q1, focuses on therapy adoption

CVRx's Q1 performance showed revenue growth but faced challenges from disruptions and increased expenses.
Strengthening market development efforts and therapy adoption are key focus areas for CVRx.
Opportunities lie in improving awareness, evidence, and access for Barostim therapy.
Navigating challenges like sales turnover and market dynamics will be crucial for CVRx's growth.

CVRx reports strong revenue growth and strategic leadership enhancements

CVRx's Q2 2024 performance showed revenue growth and strategic leadership enhancements.
While challenges like increased expenses and net losses persist, opportunities for revenue growth exist.
The company's focus on market advocacy and product development positions it for future success.

CVRx reports revenue growth and strategic focus amidst rising expenses

CVRx shows revenue growth and positive therapy outcomes but faces challenges in managing expenses. The company's financial position remains stable with a focus on strategic growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm!

NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm!

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CVRx, Inc. (“CVRx” or the “Company”) (NASDADQ: CVRX) on behalf of CVRx stockholders. Our investigation concerns whether CVRx has violated the federal securities laws and/or engaged in other unlawful business practices.

CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx, Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Investors Can Join Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm!

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRx Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm!

LOS ANGELES , Aug. 5, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CVRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

CVRx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CVRX

LOS ANGELES , Aug. 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ: CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CVRX Investors Have Opportunity to Join CVRx, Inc. Fraud Investigation with the Schall Law Firm

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for the inpatient setting as part of the Fiscal Year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule.

CVRx Announces Increased Inpatient Payment for Barostim Procedure

MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 12:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike VallieICR Westwicke443-213-0501 ir@cvrx.com Media Contact: Laura O'NeillFinn Partners402-499-8203 laura.oneill@finnpartners.com

CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference

CVRx, Inc. (NASDAQ:CVRX ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participants Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Margaret Kaczor Andrew - William Blair Frank Takkinen - Lake Street Capital Market Bill Plovanic - Canaccord Genuity Chase Knickerbocker - Craig-Hallum Capital Group Operator Ladies and gentlemen, good afternoon and welcome to the CVRx Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

CVRx, Inc. (CVRX) Q2 2024 Earnings Call Transcript

CVRx (CVRX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.56 per share a year ago.

CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates

MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024.

CVRx Reports Second Quarter 2024 Financial and Operating Results

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVRx, Inc. ("CVRx, Inc.") (NASDAQ:CVRX) concerning possible violations of federal securities laws. On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services.

Lost Money on CVRx, Inc. (CVRX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVRx, Inc. ("CVRx, Inc.") (NASDAQ:CVRX) concerning possible violations of federal securities laws. On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services.

Levi & Korsinsky Reminds CVRx, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CVRX

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVRx, Inc. ("CVRx, Inc.") (NASDAQ:CVRX) concerning possible violations of federal securities laws. On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services.

CVRx, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - CVRX

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVRx, Inc. ("CVRx, Inc.") (NASDAQ:CVRX) concerning possible violations of federal securities laws. On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services.

CVRx, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - CVRX

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVRx, Inc. ("CVRx, Inc.") (NASDAQ:CVRX) concerning possible violations of federal securities laws. On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services.

Did CVRx, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - CVRX

NEW YORK, NY / ACCESSWIRE / July 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVRx, Inc. ("CVRx, Inc.") (NASDAQ:CVRX) concerning possible violations of federal securities laws. On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services.

CVRx, Inc. (CVRX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

News for CVRx Stock (CVRX)